383 related articles for article (PubMed ID: 27421768)
1. Evaluation of intraarterial and intravenous cisplatin chemotherapy in the treatment of metastatic osteosarcoma using an orthotopic xenograft mouse model.
Robl B; Botter SM; Pellegrini G; Neklyudova O; Fuchs B
J Exp Clin Cancer Res; 2016 Jul; 35(1):113. PubMed ID: 27421768
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α.
Zhao W; Xia SQ; Zhuang JP; Zhang ZP; You CC; Yan JL; Xu GP
Mol Cell Biochem; 2016 Sep; 420(1-2):1-8. PubMed ID: 27473145
[TBL] [Abstract][Full Text] [Related]
3. Platinum disposition after intraarterial and intravenous infusion of cisplatin for osteosarcoma. Cooperative Osteosarcoma Study Group COSS.
Bielack SS; Erttmann R; Looft G; Purfürst C; Delling G; Winkler K; Landbeck G
Cancer Chemother Pharmacol; 1989; 24(6):376-80. PubMed ID: 2676224
[TBL] [Abstract][Full Text] [Related]
4. PPARγ Agonist Pioglitazone in Combination With Cisplatinum Arrests a Chemotherapy-resistant Osteosarcoma PDOX Model.
Higuchi T; Yamamoto J; Sugisawa N; Tashiro Y; Nishino H; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(1):35-40. PubMed ID: 31882549
[TBL] [Abstract][Full Text] [Related]
5. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
6. [Lethal effects of nanoliposome encapsulated cisplatin on Saos-2 cells and its distribution in nude mice bearing human].
Wang GW; Guo W; Tang XD; Peng CL; Zhao H
Beijing Da Xue Xue Bao Yi Xue Ban; 2009 Oct; 41(5):525-30. PubMed ID: 19829667
[TBL] [Abstract][Full Text] [Related]
7. Tranilast enhances the effect of anticancer agents in osteosarcoma.
Nakashima T; Nagano S; Setoguchi T; Sasaki H; Saitoh Y; Maeda S; Komiya S; Taniguchi N
Oncol Rep; 2019 Jul; 42(1):176-188. PubMed ID: 31059083
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial chemotherapy for osteosarcoma: does the result really justify the effort?
Bielack SS; Bieling P; Erttmann R; Winkler K
Cancer Treat Res; 1993; 62():85-92. PubMed ID: 8096763
[TBL] [Abstract][Full Text] [Related]
9. Effect of intra-arterial versus intravenous cisplatin in addition to systemic adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities.
Bacci G; Picci P; Avella M; Ferrari S; Casadei R; Ruggieri P; Brach del Prevert A; Tienghi A; Battistini A; Mancini A
J Chemother; 1992 Jun; 4(3):189-95. PubMed ID: 1517815
[TBL] [Abstract][Full Text] [Related]
10. Intraarterial Cisplatin and intravenous adriamycin in nonmetastatic osteosarcoma of the extremities: a single institution experience in Taiwan.
Chiu TJ; Wang JW; Chen YJ; Tang Y; Huang CH
Chang Gung Med J; 2009; 32(1):72-80. PubMed ID: 19292942
[TBL] [Abstract][Full Text] [Related]
11. Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene.
Zheng D; Wu W; Dong N; Jiang X; Xu J; Zhan X; Zhang Z; Hu Z
Mol Carcinog; 2017 Oct; 56(10):2234-2244. PubMed ID: 28543796
[TBL] [Abstract][Full Text] [Related]
12. The antitumor effect of liposome-encapsulated cisplatin on rat osteosarcoma and its enhancement by caffeine.
Karita M; Tsuchiya H; Kawahara M; Kasaoka S; Tomita K
Anticancer Res; 2008; 28(3A):1449-57. PubMed ID: 18630498
[TBL] [Abstract][Full Text] [Related]
13. Intra-arterial administration of tumor-targeting Salmonella typhimurium A1-R regresses a cisplatin-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Nelson SD; Dry SM; Li Y; Yanagawa J; Russell TA; Singh AS; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2017 Jun; 16(12):1164-1170. PubMed ID: 28494180
[TBL] [Abstract][Full Text] [Related]
14. A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.
Igarashi K; Kawaguchi K; Yamamoto N; Hayashi K; Kimura H; Miwa S; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Morinaga S; Misra S; Nelson SD; Dry SM; Li Y; Odani A; Singh SR; Tsuchiya H; Hoffman RM
Cancer Genomics Proteomics; 2020; 17(3):217-223. PubMed ID: 32345663
[TBL] [Abstract][Full Text] [Related]
15. HIF-1α-dependent miR-424 induction confers cisplatin resistance on bladder cancer cells through down-regulation of pro-apoptotic UNC5B and SIRT4.
Yu M; Ozaki T; Sun D; Xing H; Wei B; An J; Yang J; Gao Y; Liu S; Kong C; Zhu Y
J Exp Clin Cancer Res; 2020 Jun; 39(1):108. PubMed ID: 32522234
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeting Salmonella typhimurium A1-R combined with recombinant methioninase and cisplatinum eradicates an osteosarcoma cisplatinum-resistant lung metastasis in a patient-derived orthotopic xenograft (PDOX) mouse model: decoy, trap and kill chemotherapy moves toward the clinic.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li S; Han Q; Tan Y; Zhao M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(6):801-809. PubMed ID: 29374999
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA‑22 regulates autophagy and apoptosis in cisplatin resistance of osteosarcoma.
Meng CY; Zhao ZQ; Bai R; Zhao W; Wang YX; Sun L; Sun C; Feng W; Guo SB
Mol Med Rep; 2020 Nov; 22(5):3911-3921. PubMed ID: 33000186
[TBL] [Abstract][Full Text] [Related]
18. Up-regulation of survivin by AKT and hypoxia-inducible factor 1α contributes to cisplatin resistance in gastric cancer.
Sun XP; Dong X; Lin L; Jiang X; Wei Z; Zhai B; Sun B; Zhang Q; Wang X; Jiang H; Krissansen GW; Qiao H; Sun X
FEBS J; 2014 Jan; 281(1):115-28. PubMed ID: 24165223
[TBL] [Abstract][Full Text] [Related]
19. Development of Alendronate-conjugated Poly (lactic-co-glycolic acid)-Dextran Nanoparticles for Active Targeting of Cisplatin in Osteosarcoma.
Liu P; Sun L; Zhou DS; Zhang P; Wang YH; Li D; Li QH; Feng RJ
Sci Rep; 2015 Dec; 5():17387. PubMed ID: 26619950
[TBL] [Abstract][Full Text] [Related]
20. Suppressing CHD1L reduces the proliferation and chemoresistance in osteosarcoma.
Fan GT; Ling ZH; He ZW; Wu SJ; Zhou GX
Biochem Biophys Res Commun; 2021 May; 554():214-221. PubMed ID: 33813077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
